Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Trastuzumab Emtansine

Review the clinical trials studying trastuzumab emtansine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-13 of 13

Testing the use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy with Docetaxel plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Status: Active
Location: 137 locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 34 locations
Trastuzumab Emtansine Followed by Trastuzumab versus Paclitaxel in Combination with Trastuzumab for the Treatment of HER2-Positive Stage I Breast Cancer, ATEMPT 2.0 Trial
Status: Active
Location: 32 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery
Status: Active
Location: 15 locations
Trastuzumab Emtansine and Chemoradiation for the Treatment of HER2-Positive, Resectable Stage II-IVB Salivary Gland Cancer
Status: Active
Location: 12 locations
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Status: Active
Location: 8 locations
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Active
Location: 5 locations
Sequential Combination Therapy for the Treatment of Patients with De Novo Metastatic Breast Cancer, The SAPPHO Study
Status: Active
Location: 4 locations
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Status: Active
Location: 5 locations
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Status: Active
Location: 2 locations
Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Capecitabine or Trastuzumab Emtansine with Radiation Therapy for the Treatment of High-Risk Stage I-IIIB Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Tucatinib and T-DM1 for the Treatment of Patients with HER2-Positive Metastatic Solid Tumors and Brain Metastases, TUCATEMEB Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas